PDE5A and benign prostatic hyperplasia: The first scaffold is represented by tadalafil (Figure 3B), a PDE5A inhibitor approved for treatment of erectile dysfunction and benign prostatic hypertrophy that is well known to potently inhibit PDE11A4, albeit at higher concentrations [47,48].